Michelle Bloom, MD
Advanced Heart Failure and Transplant Cardiology · Mineola, NYNPI 1952569873
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $118,190 of the $165,957 with a category attached, or 71.2%. 12 manufacturers reported payments, led by Bayer at 33.7% of the total. Reporting peaked in 2019 at $58,320 and has fallen 97.5% since, to $1,462 in 2025. Among advanced heart failure and transplant cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 170 payments — averaging $976.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$56K
- Novartis$40K
- AstraZeneca$36K
- Vifor Pharma, Inc.$30K
- Abbott$2K
- Alnylam Pharmaceuticals Inc.$362
- plus $499 from 6 others
Across 2 payments — averaging $23,943 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$48K
What the payments were for
- Consulting fees$34,14921%
- Speaking & faculty fees$118,19071%
- Travel & lodging$7,0364%
- Food & beverage$5,4023%
- Other$1,1801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 33 | $55,979 |
| Novartis | 37 | $40,369 |
| AstraZeneca | 26 | $36,484 |
| Vifor Pharma, Inc. | 27 | $30,134 |
| Abbott | 27 | $2,129 |
| Alnylam Pharmaceuticals Inc. | 7 | $362 |
| Scpharmaceuticals Inc. | 3 | $185 |
| Abiomed | 1 | $91 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $72 |
| Sumitomo Pharma America, Inc. | 1 | $69 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Bridgebio Pharma, Inc. | 2 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$55,904
- ENTRESTO$38,995
- Veltassa$30,008
- FARXIGA$28,794
- CALQUENCE$1,880
- HeartMate 3 Left Ventricular Dev$852
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$388
- MitraClip$140
- ONPATTRO$135
- FUROSCIX$130
- AMVUTTRA$125
- WAINUA$125
- CardioMEMS HF System$123
How this compares
$165,957 in reported general payments places this provider in the 95th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 55 | $65,352 |
| JardianceEmpagliflozin | 36 | $29,894 |
| FarxigaDapagliflozin Propanediol | 28 | $27,500 |
| EliquisApixaban | 14 | $11,356 |
| Carvedilol | 98 | $1,083 |
| Metoprolol Succinate | 60 | $893 |
| Valsartan | 29 | $798 |
| Spironolactone | 91 | $789 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 18 | $705 |
| Atorvastatin Calcium | 44 | $480 |
| Hydralazine Hcl | 21 | $284 |
| Rosuvastatin Calcium | 22 | $270 |
| Losartan Potassium | 26 | $197 |
| Furosemide | 43 | $178 |
| ClopidogrelClopidogrel Bisulfate | 16 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $40,369 | $65,35255 claims |
| AstraZenecaFarxiga | $36,484 | $27,50028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in Mineola
- Johanna ContrerasNew York$534K
- Scott FeitellRochester$422K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Gregg LanierHawthorne$239K
- Norbert MoskovitsBrooklyn$159K
- Stephen PanValhalla$159K
- Dor LotanNew York$158K
- Nir UrielNew York$125K
- Gabriel SayerNew York$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.